ClinicalTrials.gg
CompletedNCT04519658BrigHTNUpdated Jul 24, 2023Results posted

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

A Phase 2 interventional study of CIN-107 and Placebo in Resistant Hypertension, sponsored by CinCor Pharma, Inc.. Completed at 80 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by CinCor Pharma, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
6th of 18
275 · median 197
Started
2020
with 2 others
Phase 2
5 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
2 of 18
CinCor Pharma, Inc.

Among the 18 studies testing baxdrostat in Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2020, is one of 5 in phase 2, and was the 1st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN).

03

Conditions studied

  • Resistant Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization;
  • Be at least 70% compliant to their anti-hypertensive medication regimen;
  • Has a seated BP ≥ 130/80 mmHg;
  • Agrees to comply with the and reproduction restrictions of the study; and
  • Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written according to institutional and regulatory guidelines.

Exclusion criteria

Exclusion Criteria:

  • Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;
  • Has a (BMI) > 40 kg/m2;
  • Has an upper arm circumference \< 7 or > 17 inches;
  • Has been on night shifts at any time during the 4 weeks before Screening;
  • Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);
  • Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;
  • Is not willing or not able to discontinue taking a potassium supplement;
  • Has documented estimated (eGFR) \< 45 mL/min/1.73m2
  • Has known and documented stage III or IV chronic heart failure
  • Has had a stroke, , hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;
  • Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
  • Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;
  • Has chronic permanent atrial fibrillation;
  • Has uncontrolled diabetes with glycosylated > 9.5% at Screening;
  • Has planned dialysis or kidney transplant during the course of this study;
  • Potassium \< 3.5 mEq/L;
  • Potassium > 5.0 mEq/L;
  • Is positive for antibody, virus RNA, or surface antigen;
  • Has typical consumption of ≥14 alcoholic drinks weekly.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    CIN-107 0.5mg

    Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

    Drug: CIN-107

  • Experimental
    CIN-107 1mg

    Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

    Drug: CIN-107

  • Experimental
    CIN-107 2mg

    Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

    Drug: CIN-107

  • Placebo comparator
    Placebo

    Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.

    Drug: Placebo

Interventions

  • CIN-107 tablets by mouth once daily

    Also known as: baxdrostat

  • DrugPlacebo

    placebo tablets by mouth once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Seated Systolic BP (SBP)

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Mean Seated Diastolic BP (DBP)

    Time frame: 12 weeks

  2. The Percentage of Patients Achieving a Seated BP Response <130/80 mmHg

    Time frame: 12 weeks

07

Results

Posted Jun 28, 2023

Participant flow

Participant flow — Overall Study
MilestoneCIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)Placebo
Started69706769
Completed65605667
Not completed410112

Outcome measures

PrimaryChange From Baseline in Mean Seated Systolic BP (SBP)
Time frame:
12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated Systolic BP (SBP)
mmHgmITT Population 0.5mgmITT Population 1mgmITT Population 2mgmITT Population Placebo
Change From Baseline in Mean Seated Systolic BP (SBP)-12.4 ± 15.63-17.3 ± 18.10-19.2 ± 15.84-9.8 ± 13.71
SecondaryChange From Baseline in Mean Seated Diastolic BP (DBP)
Time frame:
12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated Diastolic BP (DBP)
mmHgmITT Population 0.5mgmITT Population 1mgmITT Population 2mgmITT Population Placebo
Change From Baseline in Mean Seated Diastolic BP (DBP)-9.1 ± 9.04-11.7 ± 9.88-14.0 ± 12.42-9.3 ± 9.6
SecondaryThe Percentage of Patients Achieving a Seated BP Response <130/80 mmHg
Time frame:
12 weeks
Reported as:
Count of participants · Participants
The Percentage of Patients Achieving a Seated BP Response <130/80 mmHg
ParticipantsmITT Population 0.5mgmITT Population 1mgmITT Population 2mgmITT Population Placebo
The Percentage of Patients Achieving a Seated BP Response <130/80 mmHg21282621

Adverse events

Collected over From the time of informed consent to the end of the Follow-up Period, up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population 0.5mg0/69 (0%)0/69 (0%)6/69 (8.7%)
Safety Population 1mg0/69 (0%)2/69 (2.9%)16/69 (23.2%)
Safety Population 2mg0/67 (0%)6/67 (9%)8/67 (11.9%)
Safety Population Placebo0/69 (0%)2/69 (2.9%)10/69 (14.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSafety Population 0.5mgSafety Population 1mgSafety Population 2mgSafety Population Placebo
CellulitisInfections and infestations0/690/691/670/69
PneumoniaInfections and infestations0/690/691/670/69
Urinary tract infectionInfections and infestations0/690/691/670/69
ArthralgiaMusculoskeletal and connective tissue disorders0/690/691/670/69
DizzinessNervous system disorders0/690/691/670/69
SyncopeNervous system disorders0/690/691/670/69
Acute kidney injuryRenal and urinary disorders0/690/691/670/69
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/690/691/670/69
Respiratory failureRespiratory, thoracic and mediastinal disorders0/690/691/670/69
DehydrationMetabolism and nutrition disorders0/690/691/670/69
Most frequent other events
Most frequent other events
EventSafety Population 0.5mgSafety Population 1mgSafety Population 2mgSafety Population Placebo
Urinary tract infectionInfections and infestations3/697/696/673/69
HyperkalaemiaMetabolism and nutrition disorders2/695/692/671/69
HeadacheNervous system disorders1/695/690/672/69
FatigueGeneral disorders0/694/690/671/69
Oedema peripheralGeneral disorders0/690/690/674/69

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
<=18 years00000
Between 18 and 65 years39394132151
>=65 years30312637124
Age, Continuous
Age, Continuous(Years)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
Mean61.5 ± 10.2862.7 ± 10.1461.2 ± 10.7763.8 ± 10.7862.3 ± 10.48
Sex: Female, Male
Sex: Female, Male(Participants)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
Female33332927122
Male36373842153
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
American Indian or Alaska Native10001
Asian12126
Native Hawaiian or Other Pacific Islander00000
Black or African American2220191677
White45484751191
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
United States69706769275
Seated SBP
Seated SBP(mmHg)CIN-107 Dose 1 (0.5mg)CIN-107 Dose 2 (1mg)CIN-107 Dose 3 (2mg)PlaceboTotal
Mean147.6 ± 12.49147.7 ± 13.05147.3 ± 11.82148.9 ± 12.38147.9 ± 12.40
08

Study locations

80 sites
  • CinCor Site 16
    Birmingham, Alabama 35209, United States
  • CinCor Site 38
    Birmingham, Alabama 35294-0007, United States
  • CinCor Site 61
    Saraland, Alabama 36571, United States
  • CinCor Site 90
    Tucson, Arizona 85715, United States
  • CinCor Site 82
    Anaheim, California 92805, United States
  • CinCor Site 91
    Granada Hills, California 91344, United States
  • CinCor Site 25
    Lincoln, California 95821, United States
  • CinCor Site 73
    Los Angeles, California 90048, United States
  • CinCor Site 36
    Los Angeles, California 90057, United States
  • CinCor Site 34
    Lynwood, California 90262, United States
  • CinCor Site 14
    San Dimas, California 91773, United States
  • CinCor Site 28
    Santa Ana, California 92705, United States
  • CinCor Site 19
    Spring Valley, California 91978, United States
  • CinCor Site 32
    Tustin, California 92780, United States
  • CinCor Site 44
    West Hills, California 91405, United States
  • CinCor Site 66
    Whittier, California 90211, United States
  • CinCor Site 56
    Stamford, Connecticut 06905, United States
  • CinCor Site 30
    Clearwater, Florida 33765, United States
  • CinCor Site 13
    Fort Myers, Florida 33912, United States
  • CinCor Site 74
    Hialeah, Florida 33013, United States
  • CinCor Site 22
    Homestead, Florida 33166, United States
  • CinCor Site 20
    Jacksonville, Florida 32216, United States
  • CinCor Site 1
    Jupiter, Florida 33458, United States
  • CinCor Site 84
    Lake Worth, Florida 33467, United States
  • CinCor Site 70
    Miami, Florida 33012, United States
  • CinCor Site 89
    Miami, Florida 33032, United States
  • CinCor Site 94
    Miami, Florida 33033, United States
  • CinCor Site 5
    Port Orange, Florida 32127, United States
  • CinCor Site 9
    Saint Petersburg, Florida 33709, United States
  • CinCor Site 23
    Tampa, Florida 33606, United States
  • CinCor Site 88
    Winter Haven, Florida 33880, United States
  • CinCor Site 71
    Suwanee, Georgia 30024, United States
  • CinCor Site 11
    Meridian, Idaho 83642, United States
  • CinCor Site 15
    Addison, Illinois 60101, United States
  • CinCor Site 81
    Arlington Heights, Illinois 60005, United States
  • CinCor Site 49
    Chicago, Illinois 60607, United States
  • CinCor Site 35
    Morton, Illinois 61550, United States
  • CinCor Site 58
    Evansville, Indiana 47714, United States
  • CinCor Site 54
    West Des Moines, Iowa 50266, United States
  • CinCor Site 29
    Lexington, Kentucky 40503, United States
  • CinCor Site 24
    Lexington, Kentucky 40509, United States
  • CinCor Site 69
    New Orleans, Louisiana 70119, United States
  • CinCor Site 64
    Shreveport, Louisiana 71101, United States
  • CinCor Site 75
    Baltimore, Maryland 21201, United States
  • CinCor Site 65
    Elkridge, Maryland 21075, United States
  • CinCor Site 52
    Roseville, Michigan 48066, United States
  • CinCor Site 21
    Troy, Michigan 48085, United States
  • CinCor Site 92
    Hattiesburg, Mississippi 39401, United States
  • CinCor Site 50
    Olive Branch, Mississippi 38654, United States
  • CinCor Site 45
    Butte, Montana 59701, United States
  • CinCor Site 47
    Las Vegas, Nevada 89119, United States
  • CinCor Site 31
    Albuquerque, New Mexico 87102, United States
  • CinCor Site 4
    Bronx, New York 10455, United States
  • CinCor Site 55
    Johnson City, New York 13901, United States
  • CinCor Site 59
    Cincinnati, Ohio 45212, United States
  • CinCor Site 6
    Cincinnati, Ohio 45246, United States
  • CinCor Site 7
    Cincinnati, Ohio 45246, United States
  • CinCor Site 86
    Dayton, Ohio 45439, United States
  • CinCor Site 43
    Beaver, Pennsylvania 15066, United States
  • CinCor Site 39
    Myrtle Beach, South Carolina 29588, United States
  • CinCor Site 97
    Jackson, Tennessee 38305, United States
  • CinCor Site 42
    Knoxville, Tennessee 37920, United States
  • CinCor Site 27
    Austin, Texas 78705, United States
  • CinCor Site 80
    Carrollton, Texas 75006, United States
  • CinCor Site 79
    Dallas, Texas 75234, United States
  • CinCor Site 87
    Friendswood, Texas 77089, United States
  • CinCor Site 2
    Houston, Texas 77040, United States
  • CinCor Site 72
    Houston, Texas 77054, United States
  • CinCor Site 46
    Hurst, Texas 76054, United States
  • CinCor Site 93
    Kerville, Texas 78028, United States
  • CinCor Site 37
    McAllen, Texas 78503, United States
  • CinCor Site 85
    Sugar Land, Texas 77479, United States
  • CinCor Site 48
    Draper, Utah 84020, United States
  • CinCor Site 3
    Salt Lake City, Utah 84107, United States
  • CinCor Site 77
    Alexandria, Virginia 22304, United States
  • CinCor Site 8
    Burke, Virginia 22015, United States
  • CinCor Site 33
    Manassas, Virginia 20110, United States
  • CinCor Site 76
    Norfolk, Virginia 23510, United States
  • CinCor Site 41
    Olympia, Washington 98502, United States
  • CinCor Site 51
    Kenosha, Wisconsin 60031, United States
09

References and documents

Publications

  • Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. PubMed 36342143 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2022, 20 months.

Results were first posted in Jun 2023, 1 year after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 20 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Aug 20, 2020
StartActual
Oct 12, 2020
Primary completionActual
Jun 14, 2022
CompletionActual
Jun 14, 2022
Results first posted
Jun 28, 2023
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04519658
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Oct 12, 2020
Primary completion
Jun 14, 2022
Completion
Jun 14, 2022
Results posted
Jun 28, 2023
Last update
Jul 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion